Shivanka Research

Shivanka is advancing a pipeline of innovative therapies targeting oncology (notably advanced ER+/HER2– breast cancer), rare diseases suchs as Gaucher Disease Type-I and interstitial cystitis/bladder pain syndrome. Their lead programs include an oral SERD for breast cancer in early clinical trials with promising preclinical efficacy data, a novel therapy for IC/BPS in preclinical development, a sublingual Levodopa prodrug for Parkinson's aiming to reduce "off time," and an advanced therapy for Gaucher Disease currently in Phase III trials. The company leverages deep expertise from its leadership team with decades of experience across major pharma companies.